Earnings call
Advanced Enzyme Technologies Q2 FY27 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company said the U.S. market had some dullness in the first 2 quarters because of global factors, but expects it to pick up toward year-end. Revenue was INR2,145 million in the quarter ended September 30, 2026, up 16% year-on-year and 12% sequentially; revenue for the half year ended September 30, 2026 grew 10% over the corresponding period last year. The company completed a buyback by acquiring 2.41 million equity shares at an average price of INR289.09 per share via open market route.
The numbers management gave
Results
- Revenue was INR2,145 million in the quarter ended September 30, 2026, up 16% year-on-year and 12% sequentially; revenue for the half year ended September 30, 2026 grew 10% over the corresponding period last year.
Show source
Our top line for the quarter stood at INR2,145 million, registering a growth of 16% year-on-year and 12% on a sequential basis, while the first half of financial year '27 revenue grew by 10% over the corresponding period last year.
- EBITDA was INR721 crores in the quarter ended September 30, 2026, up 20% year-on-year and 36% sequentially, and grew 7% year-to-date.
Show source
EBITDA increased to INR721 crores, up 20% year-on-year and 36% sequentially, while the same grew by 7% on a year-to-date basis.
- EBITDA margin was 34% of revenue in the quarter ended September 30, 2026, compared with 33% in quarter 2 financial year '26 and 28% in quarter 1 financial year '27.
Show source
Consequently, the EBITDA margin stood at 34% compared to 33% in quarter 2 financial year '26 and 28% in quarter 1 financial year '27.
- Profit after tax was INR512 million in the quarter ended September 30, 2026, up 14% year-on-year, 33% sequentially and 5% YTD.
Show source
Profit after tax, PAT, stood at INR512 million, grew by 14% year-on- year basis, 33% sequential basis and 5% on a YTD basis.
- PAT margin was 24% of revenue for the quarter and 22% for the first half of financial year '27.
Show source
The PAT margin for the quarter was 24% and 22% for the first half financial year '27.
- Bio-Processing segment revenue was INR365 million in the quarter ended September 30, 2026, up 43% year-on-year and 19% sequentially; first-half fiscal growth was 37%.
Show source
The segment reported revenues of INR365 million, delivering a strong 43% year-on-year growth, 19% sequential increase and 37% growth in the first half of the fiscal.
Show 25 more statements
Results
- Bio-Processing contributed approximately 17% of Advanced Enzyme Technologies Limited's total revenues in the quarter ended September 30, 2026.
Show source
The segment contributed approximately 17% to our total revenues during the quarter.
- Specialized Manufacturing reported revenue of INR231 million in the quarter ended September 30, 2026, up 25% year-on-year and 15% over the previous quarter; first-half current fiscal growth was 32%.
Show source
Lastly, Specialized Manufacturing reported revenues of INR231 million, registering a healthy 25% year-on-year growth, 15% increase over the previous quarter and 32% growth in the first half of the current fiscal.
- Specialized Manufacturing accounted for approximately 11% of Advanced Enzyme Technologies Limited's overall revenue in the quarter ended September 30, 2026.
Show source
The segment accounted for approximately 11% of our overall revenue during the quarter.
- Consolidated revenue increased by INR300 million, or 16%, from INR1,845 million to INR2,145 million in the quarter ended September 30, 2026 compared with the corresponding prior-year quarter.
Show source
It's a 16% of growth on INR1,845 million to INR2,145 million.
- Consolidated EBITDA increased by INR121 million, or 20%, from INR601 million to INR721 million and was about 34% of revenue, compared with 33% in the corresponding prior-year quarter.
Show source
Our EBITDA increased by INR121 million, 20% growth from INR601 million to INR721 million, and this is about 34% of our revenue as compared to 33% in the correspond previous quarter.
- Consolidated profit before tax increased by INR92 million, or 15%, from INR595 million to INR688 million in the quarter ended September 30, 2026 compared with the corresponding prior-year quarter.
Show source
Profit before tax increased by INR92 million, a 15% increase from INR595 million to INR688 million.
- Consolidated PAT increased by INR64 million, or 14%, from INR447 million to INR512 million in the quarter ended September 30, 2026 compared with the corresponding prior-year quarter; PAT was about 24% of revenue.
Show source
Our PAT has increased by INR64 million, a 14% increase from INR447 million to INR512 million.
- Consolidated revenue increased by 12% sequentially from INR1,917 million to INR2,145 million in the quarter ended September 30, 2026.
Show source
On a sequential basis, which is quarter-on-quarter, our revenue increased by 12% from INR1,917 million to INR2,145 million.
- Consolidated PBT increased by INR152 million from INR535 million to INR688 million sequentially in the quarter ended September 30, 2026.
Show source
PBT increased by INR152 million from INR535 million to INR688 million.
- Consolidated PAT increased by INR126 million, or 33%, from INR386 million to INR512 million sequentially in the quarter ended September 30, 2026; PAT was about 24% of revenue compared with 20% in the previous quarter.
Show source
PAT increased by INR126 million, a 33% increase from INR386 million to INR512 million.
- Consolidated revenue for 6 months increased by INR358 million, or 10%, from INR3,704 million to INR4,062 million.
Show source
So we have 10% of growth in 6 months from INR3,704 million to INR4,062 million.
- Consolidated EBITDA for 6 months improved by INR85 million, from INR1,165 million to INR1,250 million, and was about 31% of revenue, the same percentage as last year.
Show source
And EBITDA is improved by INR85 million from INR1,165 million to INR1,250 million.
- Consolidated PBT for 6 months increased by INR78 million, from INR1,144 million to INR1,223 million, and consolidated PAT increased by INR46 million, from INR852 million to INR897 million; PAT was about 22% of the top line.
Show source
PBT increased by INR78 million from INR1,144 million to INR1,223 million, and our PAT is increased by INR46 million from INR852 million to INR897 million.
- JC Biotech sale revenue was INR200 million, EBITDA was INR29 million and PAT was INR17 million in Q2 of FY27, compared with revenue of INR186 million, EBITDA of INR37 million and PAT of INR17 million in Q2 of FY26.
Show source
JC Biotech sale numbers stood at INR200 million with the EBITDA of INR29 million and PAT of INR17 million in Q2 of FY27 as compared to INR186 million of revenue, INR37 million of EBITDA, and INR17 million of PAT during Q2 of FY26.
- JC Biotech top line for 6 months was INR395 million, compared with INR397 million.
Show source
So for 6 months, JCB top line stood at INR395 million as compared to INR397 million.
- Consolidated R&D spend, including intercompany elimination, was about 4.3% in quarter 2 compared with 3% in Q2 of FY26.
Show source
And on consolidated basis, R&D spend, if we consider the intercompany elimination, that works out to be about 4.3% during quarter 2 as compared to 3% in Q2 of FY26.
- Employee cost provisioning in the June quarter was higher by about INR1 crore, and the reversal of that INR1 crore in this quarter reduced the cost by INR2 crores overall.
Show source
So overall, INR1 crore impacted is like INR2 crores down.
- The company said around 7%, 8% of revenues came from new products in the quarter ended September 30, 2026.
Show source
But if you want the number, maybe around 7%, 8% is coming from the new products.
- Most of the growth in Human Healthcare is coming from the Biocatalyst area in the quarter ended September 30, 2026.
Show source
So most of the growth is coming from the Biocatalyst area as well when we talk about Human Healthcare.
- EBITDA margin was about 32% in FY '24 and about 31% in FY '25.
Show source
On YTD basis, this number remained unchanged at 31%.
- The company said elevated power and fuel and raw material input costs during the quarter were offset by operational efficiencies, which eliminated the risk and delivered robust margins.
Show source
Although the input costs like power and fuel and raw material remained elevated during the quarter, but our focus on operational efficiencies eliminated the risk and delivered robust margins.
- Payroll cost was lower than the previous quarter due to lower ESOP cost after reversing costs for employees who left, and slightly lower U.S. payroll cost because of some headcounts.
Show source
So these 3 different things has impacted and it's down in that sense as compared to the previous quarter.
- The company said the employee cost in this quarter was sustainable, while noting that continued hiring made it difficult to say whether that number would sustain.
Show source
So it is always -- like it's very difficult to say that that number will sustain.
Money and capital
- The company completed a buyback by acquiring 2.41 million equity shares at an average price of INR289.09 per share via open market route.
Show source
Before we discuss the performance for the quarter, we are pleased to announce that the company has successfully completed the buyback by acquiring 2.41 million equity shares at an average Page 2 of 14 Advanced Enzyme Technologies Limited November 03, 2026 price of INR289.09 per share via open market route.
- The company had INR640 crores at the end of the September quarter and spent about another INR30 crores on shares bought in October, leaving roughly INR610 crores, excluding internal accruals generated during October.
Show source
So roughly -- we should be having about INR610 crores.
What it expects ahead
What management expects
- The company said the U.S. market had some dullness in the first 2 quarters because of global factors, but expects it to pick up toward year-end.
Show source
But we expect it to pick up as we move on towards the year-end.
- The company said it will continue to guide for an overall EBITDA margin between 30% and 32%.
Show source
Mukund Kabra: It's a difficult question at this point of time to answer because a lot of things depends how it moves, but we will continue as our guidelines, which we say that between 30% to 32% on an overall basis.
- The company said it was seeing good traction and potential in the U.S. market after work on R&D and publishing papers, but could not say whether it would take 1 quarter or 2 quarters.
Show source
But what we can say is there is a lot of good traction, which is coming up again.
- The company is using an EBITDA level of 30% to 32% for calculation purposes as of now.
Show source
Mukund Kabra: So we are saying that as of now, for calculation purpose, we are going with 30% to 32% of EBITDA level.
- WELLFA was negligible in the quarter ended September 30, 2026, and Advanced Enzyme Technologies does not expect big sales numbers from WELLFA over the next 2 to 3 years.
Show source
But in terms of sales, we don't expect big numbers.
- The company is aiming for lower double-digit growth.
Show source
That is where we are aiming for.
Show 4 more statements
What management expects
- The company intends to grow by double digits, at the mid-level or lower mid-level of double digits, over the longer run.
Show source
This year, I would say that overall, we -- and for a longer run, we intend to grow by double digits, mid-level of double digits or lower mid-level of double digit.
- The company expects sustainable growth and stronger performance throughout the rest of the year. Replaced by a later filing.
Show source
We anticipate this sustainable growth and stronger performance throughout the rest of the year.
- The company anticipates that its growth trajectory will remain strong across all business segments in the foreseeable future. Replaced by a later filing.
Show source
We anticipate that our growth trajectory will remain strong across all business segments in the foreseeable future.
- The company sees some more recovery as it moves towards the year-end. Replaced by a later filing.
Show source
Mukund Kabra: We see that there are actually some more recovery as we move on towards the year-end.
What it is building and selling
Demand and pricing
- The company said it was not working directly with DSM, which it described as a competitor in the U.S.; it saw signs of a U.S. market turnaround in the coming future and hoped it would happen very soon.
Show source
DSM is one of the competitor in U.S. As of now, if you really look at it, we want U.S. to grow, and we can see some signs of it as of now and the turnaround we can see in the coming future.
- The company said the market is driven more by studies and that it is doing work in those areas; existing clients were not growing very rapidly, and the company was working to add different customers in different areas.
Show source
Particularly, if you ask me clients are growing, I don't see the existing clients are growing very rapidly at a very fast pace as of now.
Segments
- The company said SciTech’s customer base is broader, increased efficiencies and shift working raised production capacity, and R&D work is paying off.
Show source
We are a lot of -- we are working on many R&Ds in the SciTech and those are paying off right now.
Deals and partners
- The company said its numbers in Asia and Europe were positive, it was increasing customers including global players, and it was talking with a few players about potential partnerships.
Show source
We are like talking with a few players to even partner right now, but those are the futuristic things.
Risks, rules and outside factors
Outside factors
- The company is not present in the bioethanol segment, and its current revenue is not expected to be affected by Novonesis's bioethanol plans.
Show source
So current revenue, I can just say, but you never know, is not going to be affected in any of those areas.
Everything else said on the call
Group structure
- The company has separated WELLFA from Advanced as a separate company, with different people, and is working on it differently.
Show source
We have made a separate company.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Abhishek Navalgund: Congrats on good set of numbers. Sir, my first question is on the U.S. market. So could you please elaborate in terms of the future outlook as we see in the U.S. market for us?
Answer, mukund kabra
Mukund Kabra: Abhishek ji, we are progressing. I mean, there was some kind of a dullness which was there, which we can see in the first 2 quarters because of all the global things, however, it is moving. But we expect it to pick up as we move on towards the year-end.
Question
Abhishek Navalgund: Sure. And on SSPL, do we expect this growth run rate to continue or even -- or is there any one- off kind of a thing in this particular quarter?
Answer, mukund kabra
Mukund Kabra: We are seeing a good traction at this point of time. I won't say it one of the things, but I will not like you to just go with 1 quarter results as I -- we always mention that you take it as an annual. But I would say that there is a traction. There is good things which are moving on, on all the business fronts.
Question
Abhishek Navalgund: Sure. And lastly, the EBITDA run rate that we have delivered in this quarter, do you expect in the upcoming 2, 3 quarters, we'll maintain this INR70 crores run rate? Or will there be any possibility for upside or downside, both?
Answer, mukund kabra
Mukund Kabra: It's a difficult question at this point of time to answer because a lot of things depends how it moves, but we will continue as our guidelines, which we say that between 30% to 32% on an overall basis.
Question
Nikhil Upadhyay: Congrats on a good set of numbers. But just one understanding part, Mukund ji. See, in June quarter you had mentioned there was deferment of sales which had some impact on the June quarter reporting for like the revenue was lower by that amount. And it was substantially high. That was the reason you had called out. But if we adjust for that and on a regular basis, would you say we would be tracking a 12% to 13% kind of a sales growth? Or would it be like a 10% to 11% kind of a sales growth? What's our sustainable growth rate we are tracking post those onetime adjustments? Page 6 of 14 Advanced Enzyme Technologies Limited November 03, 2026 Mukund Kabra: I would say this -- yo
Answer, mukund kabra
Last quarter, we mentioned that deferment was around INR10 crores, which impacted us. This quarter also, the deferment is on a higher side. Out of that INR10 crores, we could get INR2.5 crores on a net basis. And still like INR7.5 crores is carried out for the next quarter as we will look at it. I won't say that this is one of the quarter. I would still say that there is a momentum. But I cannot give you the exact number.
Answer, mukund kabra
Yes, that is what we were talking about is a double-digit growth, lower double-digit growth. That is where we are aiming for.
Question
Nikhil Upadhyay: Okay. That's helpful. Secondly, Mukund ji, one thing, if I look at it, the way SciTech has scaled up and I was just going through our numbers -- since March '23 when we started reporting, our revenue run rate from INR40 crores is now sustainably moving towards INR80 crores, INR100 crores and the margin profile has also significantly improved from single digits to now almost sustainably 20% plus. So what is creating the traction for SciTech? And is it more broad-based across customers? Or is it specific to a few customers?
Answer, mukund kabra
Mukund Kabra: It's more broad-based. We increased a lot of efficiencies out there. We increased some shift working out there. That is where like we increase the production capacity. And when you utilize the capacity for the higher production, naturally, the efficiencies get improved. The customer base is more wider. We are a lot of -- we are working on many R&Ds in the SciTech and those are paying off right now.
Question
Nikhil Upadhyay: Okay. And last question, and I'll come back in the queue. Can you share the revenue of the top product?
Answer, mukund kabra
Mukund Kabra: Sorry, we are not sharing those numbers going through the quarters.
Question
Zaki Nasser: I think congratulations on a very hearty set of numbers. Sir, what you have mentioned, it looks like we will do a 15% kind of traction on the top line. Where do you foresee this coming from, sir? Would it be from the Human part or the Animal Nutrition or Manufacturing? And what geographies would lead the next set of growth numbers, sir?
Answer, mukund kabra
Mukund Kabra: So geography is global. We are working -- as we were always mentioning like we have three, four different horses. All the horses are running. We are working on all the different areas, different geographies, even into the Indian markets, even into the Asian markets and other areas, which are paying off. If you really look into the food areas, we have a very robust growth. You look into the animal feed area, we have a very robust growth. Even our Biocatalysis area is picking up.
Answer, mukund kabra
These are all the different horses like which will give us the growth. We are expecting U.S. to turn around. Once the turnaround happens, probably that will also start contributing.
Question
Zaki Nasser: Sure. And sir, could you just throw some light, if possible, with a few examples of what goes under our Specialized Manufacturing field, sir? Page 7 of 14 Advanced Enzyme Technologies Limited November 03, 2026 Mukund Kabra: So in Specialized Manufacturing, we make effervescent tablets, OD tablets.
Answer, mukund kabra
Again, like it is not just for the pharma area, but we do it for a lot of different areas like the cosmetic areas, for the pharma, for the nutra for the animal feed. And these are the different R&Ds which we do, how do we make a different delivery systems? For example, for feed, very different delivery systems. And these are all the things what we carry out there.
Question
Zaki Nasser: And one last question from my side. Sir, after the buyback, what would be the cash on our book, sir? And during the next few quarters, do you have any plans to deploy this?
Answer, beni rauka
Beni Rauka: As of 30th September. Mukund Kabra: So as I -- INR640 crores at the end of the September quarter, and I think like there were some around say 1 lakh -- around 7 lakh shares, which were bought in October. I don't have an exact number of October. Beni Rauka: So I think -- Mukund, let me give that number. INR640 crores, and then we spent about another INR30 crores. So roughly -- we should be having about INR610 crores. But of course, that is excluding the internal accruals, whatever we have generated during the month of October.
Answer, beni rauka
So cash is about INR610 crores, excluding the money which generated in the month of October.
Question
Lakshminarayanan K.G.: I think question regarding our largest product. There have been difficulty in terms of the other manufacturers to do the product because of the factory closures or whatever. And do you see that more players are coming into it? The main players have shut, and I don't think they have opened the factory as yet. But do you see any other player ramping up or planning to get to production? And if so, what is the lead time usually takes place before the new player trying to grab some market share? Is it -- takes a couple of years? Or how is that industry to be penetrated?
Answer, mukund kabra
Mukund Kabra: So Lakshminarayanan ji, there is no such thing that no one will come or they will come, they will not come. And you need to accept those. There are a few players which are already there in the market. Now it depends on many, many factors, just not being there you can sell. You need to have quality, you need to go through a lot of different things. And there is a lot of hard work, which company has put in the last 30, 35 years, which is paying off. And this is the area in biotechnology, you always have to improve your efficiencies, and that is what we are doing.
Answer, mukund kabra
You have to always increase the productivity. The players will come and they will go. You need to stand there, you need to figure out different applications, and that's what we are doing.
Answer, lakshminarayanan k.g
Lakshminarayanan K.G.: Got it. Sir, if I just look at our revenues over the last 6 months, what percent... Page 8 of 14 Advanced Enzyme Technologies Limited November 03, 2026 Mukund Kabra: Sorry?
Show 12 more questions
Question
Nikhil Upadhyay: Mukund, sir, two questions. One thing you mentioned that you are seeing signs of turnaround in the U.S. market. And last year, one of the challenges was around tariffs and then all this uncertainty. But what is driving, or what is giving you the confidence that the market is now turning around? And is it like the projects which we had given, and now you are seeing some of them getting commercial? If you can just spend some light on what's giving you the confidence on turnaround in U.S. market?
Answer, mukund kabra
Mukund Kabra: In the last few years or a few quarters, we spent work on a lot of R&D, publishing a lot of different papers. We are just back from the SupplySide -- SupplySide West, which happened in Vegas. And there, we saw a lot of different attractions, which is coming up, a lot of good potentials, which we are talking. At this point of time, I won't say that how long it will take, maybe 1 quarter or 2 quarters. But what we can say is there is a lot of good traction, which is coming up again.
Question
Nikhil Upadhyay: And are these products which we have already developed or we would have to go back to the R&D drawing board, develop the product, go through validation? Like, how should one understand this?
Answer, mukund kabra
Mukund Kabra: There are certain products which are already developed, right? And some products we always continue to develop. Even like developed products, we continue to do a lot of different studies, the papers, and that's how it goes, all the clinical studies, different papers, different applications, and that's a continuous process.
Question
Nikhil Upadhyay: Okay. Second question was if I look at our segmental growth, and I'm not talking of quarterly growth here. I'm taking our growth numbers from December '24 as a benchmark. We see Animal Healthcare, Food Processing, and Specialized Manufacturing sustaining a 20%, 25% quarterly growth, removing that aberration, but on average, we've grown at that rate. If you have to understand the growth parameter further, would it be right to say it is more driven by newer customers rather than more wallet share with existing customers? How would you explain this sustained growth in these 3 segments of Animal Healthcare, Food Processing, and Specialized Manufacturing?
Answer, mukund kabra
Mukund Kabra: So here, if you ask me it's more with increasing the customer base as well and developing the new products as well and approaching different geographies as well. So that's how we are doing it. Overall, if you look at it, we are very still small players compared to the global competitors, and there is a lot of room to grow. And that's what we are trying to do. Page 9 of 14 Advanced Enzyme Technologies Limited November 03, 2026 Nikhil Upadhyay: Okay.
Question
And just one last clarification. Rauka ji on the employee cost, if you look at June quarter, we had an employee cost of INR45 crores, which fell to INR40 crores this quarter. Generally, this kind of large variation we've not seen. So was there some one-off in June quarter? And is this the base employee cost we should work with?
Answer, beni rauka
Beni Rauka: Yes. So June quarter, we were just evaluating the increments. So that particular time, the provisioning was slightly higher. I think it was higher by about INR1 crore or so. So the impact of that INR1 crore is the reversal in this particular quarter. So overall, INR1 crore impacted is like INR2 crores down. And then during this quarter, ESOP cost which we were amortizing, so whatever employees who have left the company so we had to reverse that also.
Answer, beni rauka
So because of that, again the ESOP cost has gone down, so payroll cost is also down. So all these factors has impacted us. And apart from that, even in the U.S. also, the payroll cost is slightly lower because of some headcounts. So these 3 different things has impacted and it's down in that sense as compared to the previous quarter.
Question
Nikhil Upadhyay: For sustainable, run rate should be INR40 crores to INR43 crores then, if we remove these one off?
Answer, beni rauka
Beni Rauka: So I mean, whatever cost in this particular quarter, whatever you have got, that number is something sustainable in that. And you keep on hiring. So it is always -- like it's very difficult to say that that number will sustain.
Question
Lakshminarayanan K.G.: Sorry, I think my line got disconnected. I was just trying to ask a question if -- what has been the -- if you are tracking the new products and new applications that has delivered results for us, maybe in the last 1 year or in the last 6 months, what is the contribution of revenues coming from new products or new applications, which wasn't there a year back or which way you track your new product development? If you can just give some insight, it would be great.
Answer, mukund kabra
Mukund Kabra: Lakshminarayanan ji, we don't bifurcate the numbers. I don't have those bifurcations of the number, what is new product revenues and what is this as right now.
Answer, mukund kabra
Mukund Kabra: I would say it will be very approximate. But if you want the number, maybe around 7%, 8% is coming from the new products.
Answer, lakshminarayanan k.g
Lakshminarayanan K.G.: There are two parts, sir. I think one, I remember you are strengthening your sales team to outreach clients in India or outside. I want to understand how you have strengthened in the last 6 months in terms of number of people you have added, either in percentage or absolute number. I just want to get a directional view on it. And also in the European Food business, I think a couple of years back, we were trying to make inroads. Just want to understand how -- where are we in terms of the European Food business, either numbers or qualitatively?
Answer, mukund kabra
Mukund Kabra: So the numbers on the Europe is positive, even on Asian side -- Asia, Europe, both areas it is positive. We are increasing lot of different customers out there, some global players as well. We are like talking with a few players to even partner right now, but those are the futuristic things. We see a good opportunity going forward as well in the Food business at the current markets where we are operating.
Answer, mukund kabra
Mukund Kabra: We are not working directly with DSM. DSM is one of the competitor in U.S. As of now, if you really look at it, we want U.S. to grow, and we can see some signs of it as of now and the turnaround we can see in the coming future. But right now, the situation for the last 3, 4 quarters or maybe a few quarters was not very conductive. We hope that it should -- it will be turn around very soon now.
Answer, mukund kabra
Mukund Kabra: So market is more changing, dynamic. Currently, the market is driven more by the studies and other areas, and we are doing it all of those as we are moving towards that. Particularly, if you ask me clients are growing, I don't see the existing clients are growing very rapidly at a very fast pace as of now. And we are also now working on to add different, different customers in different areas. Page 11 of 14 Advanced Enzyme Technologies Limited November 03, 2026 Going forward, I don't know about the competitors, and I cannot comment on them, how they are performing and what they are doing it as of now. But this is where we are. And we are trying to work on many different areas how to grow going forward.
Answer, mukund kabra
Mukund Kabra: Difficult question, Ritika. We don't go with the segment-wise right now. We will do all the budgeting in the month of February, March, and I can give you more guidelines based on that, maybe the next year. This year, I would say that overall, we -- and for a longer run, we intend to grow by double digits, mid-level of double digits or lower mid-level of double digit. And that's what we plan.
Question
Ritika Seth: Okay. And what would be the margin?
Answer, mukund kabra
Mukund Kabra: So we are saying that as of now, for calculation purpose, we are going with 30% to 32% of EBITDA level.
Question
Abhishek Navalgund: My line got disconnected in between. So not sure if somebody has already asked this question. On this announcement by Novonesis, wherein they are going to put some more than INR6,000 crores capex in Mumbai -- capacity. What proportion of our portfolio might get -- be directly exposed to that sort of business, I mean, the segment-wise?
Answer, mukund kabra
Mukund Kabra: I don't know exactly, but what my knowledge is they are putting it more for the bioethanol purpose as of now. Bioethanol is -- and that is what I heard from the Novonesis people. This is basically for all this alcohol, which is being mixed in the petrol and other areas, and that's what their plan is to make that, and that is where they are coming. As of now, if you ask me, we are not present in that segment. So current revenue, I can just say, but you never know, is not going to be affected in any of those areas.
Answer, mukund kabra
Mukund Kabra: We see that there are actually some more recovery as we move on towards the year-end.
Question
Abhishek Kamdar: Okay. Understood. And similar -- for Biocatalysis, what are you expecting for the rest of the year? Page 12 of 14 Advanced Enzyme Technologies Limited November 03, 2026 Mukund Kabra: Yes.
Answer, mukund kabra
So most of the growth is coming from the Biocatalyst area as well when we talk about Human Healthcare. Abhishek Kamdar: Would you be able to quantify how much of Human Healthcare is in Biocatalysis?
Answer, mukund kabra
Mukund Kabra: Current quarter, it was INR66 million, I guess.
Question
Zaki Nasser: Sir, we have a very small segment in the Indian market called WELLFA. How is that performing, sir? And what percentage would it make? I know it's very small, but what is your thoughts on that, sir?
Answer, mukund kabra
Mukund Kabra: As of now, we are negligible in this quarter as well. So we're not really counting for the next 2 years, as we were already mentioned. So next 2 to 3 years, we are doing all the different activities. But in terms of sales, we don't expect big numbers.
Question
Zaki Nasser: But you would want to keep it as a part of -- I mean, as a going concern and look at it for future growth?
Answer, mukund kabra
Mukund Kabra: Yes, that is where we have separated it from Advanced. We have made a separate company. We have put a lot of different people because B2C mindset, you need a different mindset from B2B. So we are separated, including the company, people, and we are working on it very differently right now.
Question
Zaki Nasser: But sir, 3 years down the line also, how would you expect it to scale up? Do you at least foresee INR40 crores to INR50 crores kind of top line in that? Because that's good products. Products are excellent, sir, in terms of the way everything has turned out is good, but what are the aspirations for it?
Answer, mukund kabra
Mukund Kabra: See, there are very big aspirations, right? And you mentioned right, like INR30 crores to INR40 crores, but I won't be able to give you the guidance whether we will be able to achieve that in Page 13 of 14 Advanced Enzyme Technologies Limited November 03, 2026 the 3 years' time or no. And that is where it is very difficult right now to give me the numbers. It's a long-term future, what we are expecting from it. In the current 2 to 3 years, probably we are not really counting on the revenue basis.
Answer, ronak saraf
Ronak Saraf: Thank you, everyone, for taking your valuable time for attending our earnings call. We will keep you posted for any further updates. I request you all to kindly send in your questions that may remain unanswered. An audio recording and the transcript of this call will be uploaded on our website in due course. Looking forward to host you all in the next quarter. Till then, stay healthy, stay safe, and happy Diwali. Mukund Kabra: Happy Diwali to all.
Questions about this call
- When was the Advanced Enzyme Technologies Q2 FY27 earnings call transcript filed?
- Advanced Enzyme Technologies filed the transcript with the exchange on 5 Nov 2026. This page is built from that transcript.
- What does this page list?
- 47 statements from the transcript across 8 topics, 30 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 22 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.